IGC Pharma (IGC) Long-Term Investments (2011 - 2025)

IGC Pharma (IGC) posted quarterly Long-Term Investments of $25000.0 for Q3 2025, up 127.27% quarter-over-quarter from $11000.0 in Q4 2021.

IGC Pharma (IGC) Long-Term Investments (2011 - 2025) Analysis & Trends

IGC Pharma (IGC) has reported Long-Term Investments for 12 consecutive years, with $25000.0 the latest figure, recorded in Q3 2025.

In Q3 2025, Long-Term Investments changed N/A year-over-year to $25000.0; the TTM figure through Sep 2025 stood at $25000.0 (changed N/A YoY), while the FY2021 annual figure was $12000.0, up 9.09% from the prior year.
Long-Term Investments improved to $25000.0 in Q3 2025 per IGC's latest filing, from $11000.0 in the prior quarter.
Across five years, Long-Term Investments topped out at $25000.0 in Q3 2025 and bottomed at $11000.0 in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	5.79 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	9.83 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	1.77 Bn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	22.17 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	372.10 Mn
10	IGC Pharma	30.17 Mn	29.90 Mn	-	-

Download Data